Barbara Burtness
Impact in
- Otorhinolaryngology top 0.02%
- Head and Neck Cancer Studies
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
Papers in
- Oncology 185
- Cancer Immunotherapy and Biomarkers 55
- Cancer Diagnosis and Treatment 39
- Lung Cancer Research Studies 23
- HER2/EGFR in Cancer Research 21
- Pancreatic and Hepatic Oncology Research 21
-
- Head and Neck Cancer Studies 182
- Co-authors
- Julie E. Bauman (20 shared papers)Jennifer R. Grandis (5 shared papers)C. René Leemans (2 shared papers)Vivian Wai Yan Lui (2 shared papers)Daniel E. Johnson (1 shared paper)Ranee Mehra (65 shared papers)Robert L. Ferris (22 shared papers)Arlene A. Forastiere (35 shared papers)
- Journals
- Journal of Clinical Oncology (108 papers)Annals of Oncology (27 papers)Oral Oncology (16 papers)International Journal of Radiation Oncology*Biology*Physics (16 papers)Cancer (14 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Barbara Burtness
363 papers receiving 16.8k citations
Barbara Burtness's Hit Papers
Peers
Comparison fields: 5 of 139
- Otorhinolaryngology 4.7k
- Oncology 6.9k
- Cancer Research 1.9k
- Pulmonary and Respiratory Medicine 3.5k
- Immunology 1.7k
Countries citing papers authored by Barbara Burtness
This map shows the geographic impact of Barbara Burtness's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Burtness with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Burtness more than expected).
Fields of papers citing papers by Barbara Burtness
This network shows the impact of papers produced by Barbara Burtness. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Burtness. The network helps show where Barbara Burtness may publish in the future.
Co-authors
The 25 scholars most cited alongside Barbara Burtness, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 378 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Head and neck squamous cell carcinoma Hit paper breakdown → | 2020 | 2673 |
| 2 | Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial Hit paper breakdown → | 2016 | 1336 |
| 3 | Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial Hit paper breakdown → | 2016 | 869 |
| 4 | Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study Hit paper breakdown → | 2005 | 695 |
| 5 | Phase I Studies of Anti–Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin Hit paper breakdown → | 2000 | 639 |
| 6 | The changing therapeutic landscape of head and neck cancer Hit paper breakdown → | 2019 | 563 |
| 7 | The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) Hit paper breakdown → | 2019 | 516 |
| 8 | Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 Hit paper breakdown → | 2018 | 340 |
| 9 | E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx— ECOG-ACRIN Cancer Research Group Hit paper breakdown → | 2017 | 332 |
| 10 | 2005 | 223 | |
| 11 | 2019 | 218 | |
| 12 | 2005 | 212 | |
| 13 | 2013 | 159 | |
| 14 | 2018 | 158 | |
| 15 | 2021 | 148 | |
| 16 | Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update Hit paper breakdown → | 2023 | 131 |
| 17 | 2000 | 121 | |
| 18 | Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by Programmed Death Ligand-1 combined positive score Hit paper breakdown → | 2022 | 116 |
| 19 | 2019 | 111 | |
| 20 | 2017 | 109 |
About Barbara Burtness
Barbara Burtness is a scholar working on Oncology, Otorhinolaryngology, Pulmonary and Respiratory Medicine, Surgery and Radiology, Nuclear Medicine and Imaging, having authored 378 papers that have together received 17.2k indexed citations. Recurring topics across this work include Head and Neck Cancer Studies (182 papers), Lung Cancer Treatments and Mutations (76 papers), Cancer Immunotherapy and Biomarkers (55 papers), Cancer Diagnosis and Treatment (39 papers), Esophageal Cancer Research and Treatment (25 papers), Lung Cancer Research Studies (23 papers), HER2/EGFR in Cancer Research (21 papers) and Pancreatic and Hepatic Oncology Research (21 papers). The work is most often cited by research in Otorhinolaryngology (4.7k citations), Oncology (6.9k citations), Cancer Research (1.9k citations), Pulmonary and Respiratory Medicine (3.5k citations) and Immunology (1.7k citations). Barbara Burtness has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Julie E. Bauman, Jennifer R. Grandis, C. René Leemans, Vivian Wai Yan Lui, Daniel E. Johnson, Ranee Mehra, Robert L. Ferris, Arlene A. Forastiere, John D. Cramer and Joseph P. Eder. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Oral Oncology, International Journal of Radiation Oncology*Biology*Physics and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.